TSXV:CLAS.H - Post by User
Comment by
MinimumDamageon Mar 04, 2021 12:41pm
102 Views
Post# 32715947
RE:RE:Explains it best.
RE:RE:Explains it best. AngelaL - (3/4/2021 11:29:43 AM) RE:Explains it best. I am not familiar with the company's past but there is a strong record of accomplishment and achievement for their main technology, R-107. The drug has shown excellent benefit in large animal models of acute lung injury (PR from last summer) and has completed a full battery of required preclinical studies (PR last summer) and is now about to enter Phase 1 clinical trials. The Comp has wisely refocused its energy on a world-class technology targeting the Covid pandemic. I will not be surprised if we hear soon of clinical trial start and further progress.
Even though R-107 has shown excellent benefits for acute lung injury, Kalytera only holds rights to R-107 for the treatment of coronaviruses and COVID-19 infection. In turn, due to the cancelled acquisition, Salzman has retained all rights for CILI, and PAH and everything else where acute lung injuries could be treated.
For the company's past, their main program GVHD has been forfeited and turned back to the Israeli group Talent they bought if off of to free themselves of all liabilities. As you can suspect, it was a great dissapointment for shareholders since the data showed that the product worked in the prevention of GVHD. Reasons were the cost of phase three which would require a larger pharma company taking the project over and, lacking the large market size they require as well as the CBD association made it a less than attractive opportunity for them.